Shire Remains Undervalued as Takeda Weighs Higher Bid and Allergan Enters the Picture
Shire has released details of recent negotiations with Takeda, detailing three proposed (and rejected) bids from the Japanese pharmaceutical firm. Allergan is also now evaluating a potential offer for Shire. We’re maintaining our GBX 4,890 per share/$205 per ADR valuation for Shire; shares remain undervalued, in our view, and the firm’s growing plasma business and steady rare-disease portfolio contribute to its narrow moat rating. As we noted previously, we think the market’s focus on competitio...
Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.
Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.
We have operations in 27 countries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.